Knight Therapeutics: Use of PROBUPHINEâ„¢ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast

Author's Avatar
Apr 12, 2019
Article's Main Image

MONTREAL, April 12, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE™, a new treatment in the fight against opioid addiction, is now being implanted in patients across the country.